Validation & Qualification

Pharma Validation and Qualification: Ensuring Compliance Across Processes and Equipment

Qualification is the documented verification that facilities, systems, and equipment are installed, operated, and perform according to design requirements.Click to read the full article.

Validation Gaps and Rework? Lifecycle Validation Solutions

Validation and qualification gaps can manifest in several ways. Common symptoms include:Click to read the full article.

CSV not aligned to actual use during continued process verification – documentation pitfalls that trigger 483 observations

Identifying symptoms that suggest CSV is not aligned to actual use is the first step in mitigating potential compliance risks. Common indicators include:Click to read the full article.

Inadequate worst-case justification during change control review – documentation pitfalls that trigger 483 observations

The first step in addressing inadequate worst-case justifications is recognizing the symptoms or signals that indicate a problem may exist within the change control process. These signals often manifest as…

Periodic review overdue during validation lifecycle – documentation pitfalls that trigger 483 observations

Identifying signals that indicate a deviation such as overdue periodic reviews can vary from informal reports to formal deviations logged in quality systems. Below are some observable symptoms:Click to read…

Incomplete impact assessment during tech transfer validation – how to prevent repeat validation failures

Addressing Incomplete Impact Assessments in Tech Transfer Validation to Prevent Future Failures The pharmaceutical industry faces numerous challenges during the technology transfer of manufacturing processes and product formulations. One significant…

Revalidation not triggered after change during tech transfer validation – risk-based validation strategy aligned to FDA/EMA

When a tech transfer is executed, various symptoms may signal that revalidation is required but not performed. Key signals to monitor include:Click to read the full article.

Periodic review overdue during validation lifecycle – risk-based validation strategy aligned to FDA/EMA

Investigating Periodic Review Overdue During the Validation Lifecycle In the realm of pharmaceutical manufacturing and quality assurance, having an overdue periodic review during the validation lifecycle can raise significant concerns…

Incomplete impact assessment during requalification planning – regulatory deficiency analysis and remediation roadmap

Identifying early signals of incomplete impact assessments is key to mitigating risks associated with requalification. Symptoms may present themselves in various forms:Click to read the full article.

PPQ acceptance criteria not met during inspection readiness – how to prevent repeat validation failures

Identifying early warning signs is crucial when PPQ acceptance criteria are at risk of failing. Symptoms may manifest during routine checks or as part of an internal audit. Key indicators…

Incomplete impact assessment during inspection readiness – documentation pitfalls that trigger 483 observations

Signs of incomplete impact assessments typically emerge in both manufacturing and laboratory environments. Here are a few key symptoms that may indicate a problem:Click to read the full article.

CSV not aligned to actual use during validation lifecycle – risk-based validation strategy aligned to FDA/EMA

Aligning CSV to Actual Use in the Validation Lifecycle: An Investigation Guide In the complex arena of pharmaceutical operations, the alignment of Computerized System Validation (CSV) with actual use during…